This study was undertaken to address the effects of fetal mesencephalic
tissue transplantation on the
serotonin system in a rat model of
Parkinson's disease (PD) while also investigating the usefulness of 4-[18F]-ADAM (a
serotonin transporter imaging agent) coupled with micro-PET for imaging
serotonin transporters (SERTs). A PD model was induced by unilateral injection of
6-hydroxydopamine (6-OHDA) into the right medial forebrain bundle of the nigrostriatal pathway, while
cell transplantation was performed via intrastriatal injection of mesencephalic brain tissue dissected from embryonic (E14) rats. The 4-[18F]-ADAM/micro-PET scanning was performed following both
6-OHDA lesioning and
transplantation. Immunohistochemistry (IHC) studies were also performed following the final PET scan, and the results were compared to show
a 17-43% decrease in the specific uptake ratio (SUR) and a 23-52% decrease in
serotonin transporter immunoreactivity (SERT-ir) within various brain regions on the lesioned side. The number of
methamphetamine-induced rotations also decreased significantly at the 4th week postgraft. In addition, striatal SUR and the SERT-ir levels were restored to 77% and 83% 5 weeks postgraft. These results suggest that
Parkinson's disease also affects the serotonergic system, while both the dopaminergic and serotonergic systems can be partially restored in a rat model of PD after E14 mesencephalic
tissue transplantation. In addition, we have also determined that 4-[18F]-ADAM/micro-PET can be used to detect serotonergic neuron loss, monitor the progress of
Parkinson's disease, and oversee the effectiveness of
therapy.